NasdaqGM:CRVSBiotechs
Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS?
In March 2026, Corvus Pharmaceuticals filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, adding flexibility to issue common and preferred stock, debt, warrants and units to support ongoing operations.
This expanded financing capacity sits alongside a sharp reduction in full-year 2025 net loss to US$15.28 million and continued clinical progress for lead candidate soquelitinib, together reshaping how investors may view the...